West Pharmaceutical
747 hedge funds and large institutions have $22.9B invested in West Pharmaceutical in 2024 Q4 according to their latest regulatory filings, with 108 funds opening new positions, 296 increasing their positions, 257 reducing their positions, and 79 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 4 → 10 (+6)
37% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 79
15% more repeat investments, than reductions
Existing positions increased: 296 | Existing positions reduced: 257
11% more capital invested
Capital invested by funds: $20.5B → $22.9B (+$2.35B)
2% more funds holding
Funds holding: 729 → 747 (+18)
1.88% more ownership
Funds ownership: 94.55% → 96.43% (+1.9%)
44% less call options, than puts
Call options by funds: $77.4M | Put options by funds: $139M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VanEck Associates
New York
|
+$213M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$196M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$177M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$156M |
| 5 |
D.E. Shaw & Co
New York
|
+$132M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APG Asset Management
Amsterdam,
Netherlands
|
-$274M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$232M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$173M |
| 4 |
ProShare Advisors
Bethesda,
Maryland
|
-$168M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$158M |
WST Hedge Fund Activity: Q4 2024 in Review
747 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q4 2024, worth a combined $22.9B — up 11% from $20.5B a quarter earlier.
Buyers outnumbered sellers: 108 funds opened new WST positions and 79 closed out — a net gain of 29 holders — while 296 added to existing stakes and 257 trimmed.
The largest buyer was VanEck Associates, adding an estimated $213M. The largest seller was APG Asset Management, cutting an estimated $274M.
- 747 institutional investors held West Pharmaceutical (WST) as of Q4 2024, up from 729 in Q3 2024.
- Funds reported $22.9B of West Pharmaceutical stock for Q4 2024, up 11% quarter-over-quarter.
- 108 funds opened new West Pharmaceutical positions in Q4 2024 and 79 closed out, a net change of +29 holders.
- The largest West Pharmaceutical buyer in Q4 2024 was VanEck Associates, an estimated $213M added.
- The largest West Pharmaceutical seller in Q4 2024 was APG Asset Management, an estimated $274M sold.
Based on aggregated 13F filings for Q4 2024.